Graves’ orbitopathy (GO), also referred to as thyroid eye disease (TED) or endocrine orbitopathy (EO), is the most common extrathyroidal manifestation of Graves’ disease, affecting approximately 25–40% of patients. The pathogenesis of GO is complex and multifactorial, primarily involving autoimmune processes driven by antibodies against the thyrotropin receptor. These antibodies interact with both the TSH receptor and the insulin-like growth factor 1 receptor, leading to the activation of orbital fibroblasts, which results in chronic inflammation, soft tissue swelling, and fibrosis. The clinical presentation varies from mild symptoms to severe complications, such as dysthyroid optic neuropathy. Smoking remains the most critical modifiable risk factor, significantly worsening prognosis and reducing treatment efficacy. Diagnosis relies on a comprehensive assessment, including the Clinical Activity Score, laboratory evaluation of TRAb levels, and orbital imaging to determine disease activity and severity. Treatment strategies depend on the clinical phase: intravenous glucocorticosteroids are the first-line therapy for active moderate-to-severe disease, while modern biological therapies are increasingly used for refractory cases. In the inactive phase, surgical and rehabilitative interventions are primarily indicated. Due to the potential for relapse and the impact on quality of life, a multidisciplinary approach involving endocrinologists and ophthalmologists is essential for long-term management and improved patient outcomes.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has become one of the most common chronic liver diseases worldwide, representing a major global health challenge closely linked to metabolic syndrome, obesity, and type 2 diabetes mellitus (TD2M). The condition is characterized by a multisystem nature driven by complex multifactorial mechanisms, including insulin resistance, lipotoxicity, mitochondrial dysfunction, genetic predispositions, and gut-liver axis alterations. Although liver biopsy remains the gold standard, non-invasive markers and advanced imaging methods are of key importance for early risk stratification. Furthermore, while liver-related complications such as fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) are significant, cardiovascular disease remains the leading cause of mortality in patients with MASLD. Current management relies primarily on lifestyle modifications, targeted pharmacotherapy (such as pioglitazone, GLP-1 receptor agonists, SGLT-2 inhibitors), and novel experimental therapies. Consequently, MASLD requires a multidisciplinary approach emphasizing early diagnosis, risk stratification, and comprehensive treatment of both hepatic and extrahepatic manifestations.
Cardiac sarcoidosis (CS) is a critical and frequently underdiagnosed phenotype of sarcoidosis, characterized by non-caseating granulomatous infiltration of the myocardium. This review synthesizes current knowledge regarding the pathogenesis, diagnosis, and management of CS. The disease manifests with a heterogeneous clinical spectrum ranging from asymptomatic conduction abnormalities to life-threatening ventricular arrhythmias and heart failure. Diagnosis remains challenging due to the patchy distribution of granulomas, which limits the sensitivity of endomyocardial biopsy. Consequently, a multimodal diagnostic approach is essential, integrating advanced imaging modalities such as cardiac magnetic resonance (CMR) with late gadolinium enhancement (LGE) and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). These tools not only facilitate detection but also enable the differentiation of active inflammation from chronic fibrosis. Histopathological assessment, supported by specific immunophenotyping and electron microscopy, remains the gold standard for confirming diagnosis and excluding mimics like giant cell myocarditis or infectious granulomatous diseases. Management requires a multidisciplinary strategy combining immunosuppressive therapy, primarily corticosteroids and steroid-sparing agents, with guideline-directed cardiac care, including implantable cardioverter-defibrillators for arrhythmia risk stratification. Emerging biomarkers and artificial intelligence-driven imaging analysis promise to further refine risk stratification and therapeutic monitoring, advancing precision medicine in this complex disorder.